Featuring news, events and industry trends
BASF Honored with Two Chemical Week 2021 Sustainability Awards

Chemical Week has named BASF winner of the Best Sustainable Feedstock Initiative award and the Best Sustainable Product award during the Chemical Week’s 2021 Sustainability Awards, which honor chemical producers’ excellence in environmental, social, and governance (ESG) reporting, sustainable product development, and environmental programs. BASF

BASF, a German multinational chemical company and the largest chemical producer in the world, with a presence in Tarrytown, was selected as a winner of the two awards from among 64 submissions by nearly 40 companies.

The Best Sustainable Feedstock award recognizes an important milestone BASF reached on its path toward sustainable palm. In 2020 the company sourced 100 percent of its palm (kernel) oils exclusively from sources physically certified by the Roundtable on Sustainable Palm Oil (RSPO).
Regeneron Extends Hearing Loss Gene Therapy Pact With Decibel

Tarrytown headquartered, Regeneron Pharmaceuticals Inc has extended the research term of its collaboration with Decibel Therapeutics Inc to discover and develop gene therapies for hearing loss.

  • The research term is extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Q4 of 2022.

  • Under the collaboration launched in 2017, Decibel is developing three gene therapy programs targeting congenital, monogenic hearing loss with Regeneron.

  • Decibel plans to initiate in 2022 a Phase 1/2 clinical trial of DB-OTO, the Company's lead gene therapy candidate.

  • DB-OTO is designed to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene.

  • Decibel is also advancing AAV.103 and AAV.104, gene therapy programs targeting other monogenic forms of hearing loss, with Regeneron.
Westchester Medical Center’s David Kronn, MD, Presents at 14th Annual International Congress of Inborn Errors of Metabolism 2021 Conference 

Dr. David Kronn, MD was a featured panelist for “Pursuing More Effective Diagnosis and Treatment of Pompe Disease: Applying New Advances into Practice” during the Annual International Congress of Inborn Errors of Metabolism 2021 Conference, which took place on November 22nd.

As noted in the symposium synopsis: "Pompe disease is a rare, inherited lysosomal storage disorder caused by aberrations in the glucosidase alpha (GAA) gene that lead to deficient GAA activity and a toxic buildup of glycogen in muscle and other tissues. It is classified as infantile-onset PD (IOPD) or late-onset PD (LOPD). Without ERT, IOPD is fatal by age 2 and LOPD is associated with varying degrees of morbidity and mortality. Early diagnosis is critical to ensure timely initiation of ERT and to improve long-term prognosis."
Teladoc Health CEO: We're Defining a New Category of Virtual Whole-Person Care

Purchase headquartered Teladoc Health’s CEO Jason Gorevic joined ‘Closing Bell’ on its investor day to discuss the company’s growth plan to double the company’s revenue.
Navigating Technology Transfers from Research Institutions, December 9 at 12 PM

Research institutions like universities and federal research labs, are gold mines of key opinion leaders and innovative technologies that can be mined by entrepreneurs. Technology transfer professionals are working to build partnerships with entrepreneurs to bring technologies to market. These professionals can help companies find expert advisors, service providers, and funding to grow your company and demonstrate value in the clinic. Through a panel discussion and live Q&A with seasoned experts, you'll learn how to partner with research institutions.

Please join this Society of Physician Entrepreneurs (SoPE) and GW Technology Commercialization Office webinar on December 9, 2021 and learn how medical startup companies can transfer technologies from research institutions.

Date: December 9, 2021
Time: 12:00 PM

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.